Literature DB >> 2878938

Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration.

A Starke, T Imamura, R H Unger.   

Abstract

The glucagon-suppressing activity of insulin and somatostatin were compared at high and low glucose concentrations. In normal dogs made hyperglucagonemic by phloridzin pretreatment, insulin and somatostatin suppressed glucagon at rates of 47 +/- 8 and 35 +/- 8%/h (NS), respectively, despite profound hypoglycemia. In severely hyperglycemic alloxan-diabetic dogs, insulin and somatostatin suppressed glucagon at rates of 48 +/- 13 and 54 +/- 6%/h, respectively, not different from the nondiabetic dogs. After phloridzin pretreatment to eliminate hyperglycemia in the diabetic dogs, insulin and somatostatin suppressed 51 +/- 8 and 31 +/- 10%/h (NS), respectively. Glucose infused in the phloridzin-pretreated insulin-deprived group suppressed glucagon only partially; insulin was required to reduce it further. We conclude that insulin and somatostatin suppress glucagon at similar rates irrespective of ambient glucose levels, and that diabetic hyperglucagonemia represents the summation of stimulation by insulin lack minus suppression by the associated hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2878938      PMCID: PMC423975          DOI: 10.1172/JCI112784

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  Inhibition of pancreatic glucagon release by somatostatin: in vitro.

Authors:  J Iversen
Journal:  Scand J Clin Lab Invest       Date:  1974-04       Impact factor: 1.713

2.  Somatostatin: hypothalamic inhibitor of the endocrine pancreas.

Authors:  D J Koerker; W Ruch; E Chideckel; J Palmer; C J Goodner; J Ensinck; C C Gale
Journal:  Science       Date:  1974-04-26       Impact factor: 47.728

3.  Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

Authors:  C H Mortimer; W M Tunbridge; D Carr; L Yeomans; T Lind; D H Coy; S R Bloom; A Kastin; C N Mallinson; G M Besser; A V Schally; R Hall
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

4.  Insulin control of glucagon release from insulin-deficient rat islets.

Authors:  K D Buchanan; W A Mawhinney
Journal:  Diabetes       Date:  1973-11       Impact factor: 9.461

5.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

6.  Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance.

Authors:  W A Müller; G R Faloona; R H Unger
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

7.  Insulin and glucose as modulators of the amino acid-induced glucagon release in the isolated pancreas of alloxan and streptozotocin diabetic rats.

Authors:  A S Pagliara; S N Stillings; M W Haymond; B A Hover; F M Matschinsky
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

8.  The effect of experimental insulin deficiency on glucagon secretion.

Authors:  W A Müller; G R Faloona; R H Unger
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

9.  Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics.

Authors:  P Raskin; Y Fujita; R H Unger
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

10.  The effect of insulin on the alpha-cell response to hyperglycemia in long-standing alloxan diabetes.

Authors:  J T Braaten; G R Faloona; R H Unger
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

View more
  25 in total

Review 1.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

2.  Intra-islet insulin permits glucose to directly suppress pancreatic A cell function.

Authors:  C J Greenbaum; P J Havel; G J Taborsky; L J Klaff
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

3.  Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells.

Authors:  E Vieira; A Salehi; E Gylfe
Journal:  Diabetologia       Date:  2006-11-29       Impact factor: 10.122

4.  Differences in protein and energy metabolism following portal versus systemic administration of insulin in diabetic dogs.

Authors:  E-J Freyse; U Fischer; S Knospe; G C Ford; K S Nair
Journal:  Diabetologia       Date:  2006-01-31       Impact factor: 10.122

5.  The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia.

Authors:  M Kim; E J Lee; H M Shin; H S Jung; T K Kim; T N Kim; M J Kwon; S H Lee; B D Rhee; J H Park
Journal:  J Endocrinol Invest       Date:  2017-04-08       Impact factor: 4.256

Review 6.  Paracrine signaling in islet function and survival.

Authors:  Sean M Hartig; Aaron R Cox
Journal:  J Mol Med (Berl)       Date:  2020-02-17       Impact factor: 4.599

7.  Glucagon gene transcription is negatively regulated by insulin in a hamster islet cell line.

Authors:  J Philippe
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

8.  Glucagon sensitivity and clearance in type 1 diabetes: insights from in vivo and in silico experiments.

Authors:  Ling Hinshaw; Ashwini Mallad; Chiara Dalla Man; Rita Basu; Claudio Cobelli; Rickey E Carter; Yogish C Kudva; Ananda Basu
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-07-07       Impact factor: 4.310

9.  Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells.

Authors:  T Hamaguchi; H Fukushima; M Uehara; S Wada; T Shirotani; H Kishikawa; K Ichinose; K Yamaguchi; M Shichiri
Journal:  Diabetologia       Date:  1991-11       Impact factor: 10.122

10.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.